Nothing Special   »   [go: up one dir, main page]

ES2117052T3 - Induccion de respuestas de linfocitos t citotoxicos. - Google Patents

Induccion de respuestas de linfocitos t citotoxicos.

Info

Publication number
ES2117052T3
ES2117052T3 ES92917479T ES92917479T ES2117052T3 ES 2117052 T3 ES2117052 T3 ES 2117052T3 ES 92917479 T ES92917479 T ES 92917479T ES 92917479 T ES92917479 T ES 92917479T ES 2117052 T3 ES2117052 T3 ES 2117052T3
Authority
ES
Spain
Prior art keywords
antigen
formulation
ctl
responses
induction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92917479T
Other languages
English (en)
Other versions
ES2117052T5 (es
Inventor
Syamal Raychaudhuri
William H Rastetter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idec Pharmaceuticals Corp
Original Assignee
Idec Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24954233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2117052(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idec Pharmaceuticals Corp filed Critical Idec Pharmaceuticals Corp
Publication of ES2117052T3 publication Critical patent/ES2117052T3/es
Application granted granted Critical
Publication of ES2117052T5 publication Critical patent/ES2117052T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE PRESENTAN METODOS Y COMPOSICIONES UTILES PARA INDUCIR UNA RESPUESTA CITOTOXICA DEL LINFOCITO T (CTL) EN UN HUMANO O UN ANIMAL DOMESTICO O AGRICOLAMENTE IMPORTANTE. EL METODO INCLUYE LOS PASOS DE SUMINISTRAR EL ANTIGENO AL CUAL SE DESEA LA RESPUESTA CTL Y SUMINISTRAR UNA FORMULACION DE ANTIGENO QUE COMPRENDE, CONSTA O CONSISTE ESENCIALMENTE DE DOS O MAS DETERGENTES ESTABILIZANTES, UN AGENTE FORMADOR DE MICELO, Y UN ACEITE. ESTA FORMULACION DE ANTIGENO ES PREFERIBLEMENTE CARENTE DE UN COMPONENTE PEPTIDO INMUNOESTIMULANTE, O TIENE NIVELES SUFICIENTEMENTE BAJOS DE DICHO COMPONENTE QUE NO DISMINUYAN LA DESEADA RESPUESTA CTL. ESTA FORMULACION SE SUMINISTRA COMO UNA EMULSION DE ACEITE EN AGUA ESTABLE.
ES92917479T 1991-07-25 1992-07-24 Induccion de respuestas de linfocitos t citotoxicos. Expired - Lifetime ES2117052T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73506991A 1991-07-25 1991-07-25
US735069 1991-07-25

Publications (2)

Publication Number Publication Date
ES2117052T3 true ES2117052T3 (es) 1998-08-01
ES2117052T5 ES2117052T5 (es) 2004-12-01

Family

ID=24954233

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92917479T Expired - Lifetime ES2117052T5 (es) 1991-07-25 1992-07-24 Induccion de respuestas de linfocitos t citotoxicos.

Country Status (27)

Country Link
US (2) US5585103A (es)
EP (1) EP0596032B2 (es)
JP (1) JP3939746B2 (es)
KR (1) KR100198868B1 (es)
AT (1) ATE166578T1 (es)
AU (1) AU666127B2 (es)
BG (1) BG62240B1 (es)
BR (1) BR9206310A (es)
CA (1) CA2113720A1 (es)
CZ (1) CZ288048B6 (es)
DE (1) DE69225710T3 (es)
DK (1) DK0596032T4 (es)
ES (1) ES2117052T5 (es)
FI (2) FI108114B (es)
HU (2) HU220295B (es)
IE (1) IE922436A1 (es)
IL (1) IL102639A (es)
MX (1) MX9204376A (es)
NO (1) NO317203B1 (es)
OA (1) OA09880A (es)
PH (1) PH30906A (es)
RO (1) RO116459B1 (es)
RU (1) RU2129439C1 (es)
SK (1) SK282920B6 (es)
TW (1) TW349867B (es)
WO (1) WO1993001831A1 (es)
ZA (1) ZA925614B (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US6197311B1 (en) * 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
CA2158281A1 (en) * 1993-03-15 1994-09-29 Jay A. Berzofsky Peptide coated dendritic cells as immunogens
GB9314623D0 (en) * 1993-07-14 1993-08-25 Nordion Int Inc Localization and therapy with agents directed against prostate specific antigen in breast cancer
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM446594A0 (en) * 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US5820880A (en) * 1995-06-07 1998-10-13 The United States Of America As Represented By The Secretary Of The Army Liposomal formulation
CA2279204C (en) * 1997-01-30 2005-11-15 Chiron Corporation Use of microparticles with adsorbed antigen to stimulate immune responses
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
EP0983086B1 (en) * 1997-02-05 2007-08-29 Jean-Claude Bystryn pH-SENSITIVE LIPOSOMES AND OTHER TYPES OF ENCAPSULATED VACCINES CONTAINING IMMUNOMODULATORS, AND METHODS FOR MAKING AND USING SAME
AT405939B (de) * 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
US6632619B1 (en) * 1997-05-16 2003-10-14 The Governors Of The University Of Alberta Microfluidic system and methods of use
JP2002503336A (ja) * 1997-05-16 2002-01-29 アルバータ リサーチ カウンシル 微量流通システムおよびその使用方法
DE69815692T2 (de) * 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
ZA988461B (en) * 1997-09-18 1999-03-30 Idec Pharma Corp Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
US6858386B1 (en) * 1998-05-21 2005-02-22 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US6949339B1 (en) 1998-05-21 2005-09-27 Diadexus, Inc. Method of diagnosing, monitoring, and staging colon cancer
EP1131084A4 (en) * 1998-10-30 2001-12-19 Genetics Inst INHIBITION OF DIFFERENTIATION OF CYTOTOXIC T CELLS BY P-SELECTINE LIGAND ANTAGONISTS (PSGL)
CA2350776C (en) * 1998-11-10 2011-05-03 Emory University Novel mitogenic regulators
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
US20050244434A1 (en) * 1999-08-12 2005-11-03 Cohen David I Tat-based tolerogen compositions and methods of making and using same
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
JP3524537B2 (ja) * 1999-11-22 2004-05-10 ディアデクサス インコーポレーテッド 癌の診断、モニタリング、ステージング、イメージングおよび処置のための新規方法
US7238471B1 (en) * 1999-11-23 2007-07-03 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating breast cancer
US20020048777A1 (en) * 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
CA2410436A1 (en) * 2000-05-26 2001-12-06 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US7229623B1 (en) * 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
WO2006033665A1 (en) * 2004-03-16 2006-03-30 Inist Inc. Tat-based vaccine compositions and methods of making and using same
AU2002231621A1 (en) 2000-11-09 2002-05-21 Immunolex Laboratories Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
RU2303264C2 (ru) * 2001-02-19 2007-07-20 Мерк Патент Гмбх Способ идентификации эпитопов т-клеток и его применение для получения молекул со сниженной иммуногенностью
WO2003104429A2 (en) * 2002-06-10 2003-12-18 Idec Pharmaceuticals Corporation Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
JP2006516883A (ja) 2002-09-19 2006-07-13 アメリカ合衆国 Ｐ．アリアシポリペプチド、ユウガイサシチョウバエポリペプチド、および使用法
DE60327366D1 (de) 2002-10-29 2009-06-04 Fundacao Oswaldo Cruz Lutzomyia longipalpis-polypeptide und verwendungsverfahren
WO2004087204A2 (en) * 2003-04-04 2004-10-14 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions
UA84024C2 (ru) * 2003-07-24 2008-09-10 Мериал Лимитед Новые вакцинные композиции, которые содержат эмульсию типа "масло в воде"
CA2618306C (en) 2005-08-08 2014-10-21 Oregon Health & Science University Inactivating pathogens with hydrogen peroxide for vaccine production
US20100130425A1 (en) 2005-09-09 2010-05-27 Oregon Health & Science University Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
EP2441493B1 (en) 2006-03-14 2014-05-07 Oregon Health and Science University Methods for producing an immune response to tuberculosis
EP2420246A1 (en) 2006-04-20 2012-02-22 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Methods and compositions based on shiga toxin type 1 protein
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8273361B2 (en) 2006-09-26 2012-09-25 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
TWI441648B (zh) * 2007-01-03 2014-06-21 Oncotherapy Science Inc Ｆｏｘｐ３胜肽疫苗
WO2008106551A2 (en) 2007-02-28 2008-09-04 The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv. Brachyury polypeptides and methods for use
NZ601827A (en) * 2007-10-18 2014-01-31 Bavarian Nordic Inc Use of mva to treat prostate cancer
WO2010017209A2 (en) 2008-08-04 2010-02-11 The Government Of The Usa As Represented By The Secretary Of The Department Of Health And Human Services Membrane proximal region of hiv gp41 anchored to the lipid layer of a virus-like particle vaccine
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
US8530431B2 (en) 2009-03-23 2013-09-10 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides
US8722064B2 (en) 2009-06-05 2014-05-13 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
CA2776922A1 (en) 2009-10-07 2011-04-14 Uvic Industry Partnerships Inc. Vaccines comprising heat-sensitive transgenes
US9181306B2 (en) 2009-10-16 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
EP3263124A1 (en) 2009-11-20 2018-01-03 Oregon Health & Science University Methods for producing an immune response to tuberculosis
WO2011112599A2 (en) 2010-03-12 2011-09-15 The United States Of America, As Represented By The Secretary. Department Of Health & Human Services Immunogenic pote peptides and methods of use
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
LT2734544T (lt) 2011-07-18 2021-04-26 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Su poliomavirusu susijusios patologijos slopinimo metodai ir kompozicijos
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
WO2013152352A1 (en) 2012-04-06 2013-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Live, attenuated rubella vector to express vaccine antigens
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
MX2014014683A (es) 2012-06-06 2015-02-24 Bionor Immuno As Peptidos derivados de proteinas virales para usarse como inmunogenos y reactivos de dosificacion.
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150224181A1 (en) 2012-09-14 2015-08-13 The United States Of America As Represented By The Secretary Department Of Health And Human Se Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
US20150283220A1 (en) 2012-10-19 2015-10-08 Bavarian Nordic, Inc. Methods and compositions for the treatment of cancer
JP6426706B2 (ja) 2013-04-18 2018-11-21 イミューン デザイン コーポレイション がん処置で使用するためのｇｌａ単剤療法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
WO2015051245A1 (en) 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
JP6758185B2 (ja) 2013-12-13 2020-09-23 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ マルチエピトープｔａｒｐペプチドワクチンおよびその使用
US9931393B2 (en) 2013-12-20 2018-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic JC polyomavirus compositions and methods of use
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CN116196403A (zh) 2015-08-03 2023-06-02 美国卫生和人力服务部 Brachyury缺失突变体、编码该缺失突变体的非酵母载体及其用途
ES2929274T3 (es) 2016-05-10 2022-11-28 Najit Tech Inc Inactivación de patógenos y producción de vacunas inactivadas altamente inmunógenas utilizando un proceso de oxidación dual
EP3703745B1 (en) 2017-11-04 2024-04-10 Nevada Research & Innovation Corporation Immunogenic conjugates and methods of use thereof
ES2993834T3 (en) 2018-12-04 2025-01-10 Univ Rockefeller Hiv vaccine immunogens
EP4103587A1 (en) 2020-02-14 2022-12-21 Immunor AS Corona virus vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3083142A (en) * 1958-02-27 1963-03-26 Glaxo Group Ltd Improved swine erysipelas vaccine
US3790665A (en) * 1968-02-23 1974-02-05 Haver Lockhart Labor Inc Injectable adjuvant,method of preparing same and compositions including such adjuvant
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US4117113A (en) * 1974-06-25 1978-09-26 National Research Development Corporation Immunological preparations
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
US4707443A (en) * 1985-04-19 1987-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Soluble interleukin-2 receptor as a disease indicator and a method of assaying the same
WO1988002634A1 (en) * 1986-10-20 1988-04-21 Chiron Corporation Vaccine for use in the therapeutic treatment of hsv
US4778784A (en) * 1987-01-07 1988-10-18 Baylor College Of Medicine Cyclic peptide and method of use for inducing an immunological response to hepatitis B virus
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2017507C (en) † 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
EP0405315B1 (en) * 1989-06-30 1995-08-23 American Cyanamid Company Use of a phagocyte-activating agent : LPS or IL-2 for the manufacture of a medicament for treating staphylococcus aureus infection in cows
AU1025692A (en) * 1991-02-06 1992-08-13 Ciba-Geigy Ag Novel chimeric antiidiotypic monoclonal antibodies

Also Published As

Publication number Publication date
JP3939746B2 (ja) 2007-07-04
EP0596032A4 (en) 1994-08-17
WO1993001831A1 (en) 1993-02-04
IL102639A (en) 1997-03-18
KR100198868B1 (ko) 1999-06-15
CA2113720A1 (en) 1993-02-04
SK8994A3 (en) 1994-11-09
DK0596032T4 (da) 2004-07-26
ATE166578T1 (de) 1998-06-15
HU211299A9 (en) 1995-11-28
CZ288048B6 (cs) 2001-04-11
RO116459B1 (ro) 2001-02-28
IE922436A1 (en) 1993-01-27
BG98410A (bg) 1995-02-28
US5585103A (en) 1996-12-17
HU220295B (hu) 2001-11-28
EP0596032B2 (en) 2004-04-07
NO317203B1 (no) 2004-09-20
DK0596032T3 (da) 1998-10-12
FI940335L (fi) 1994-03-24
FI940335A0 (fi) 1994-01-24
DE69225710T3 (de) 2004-10-14
MX9204376A (es) 1993-02-01
DE69225710T2 (de) 1998-09-24
JPH06509344A (ja) 1994-10-20
OA09880A (en) 1994-09-15
FI20011187L (fi) 2001-06-05
NO940218L (no) 1994-03-25
FI108114B (fi) 2001-11-30
BR9206310A (pt) 1995-04-25
HUT69784A (en) 1995-09-28
IL102639A0 (en) 1993-01-14
BG62240B1 (bg) 1999-06-30
HU9400202D0 (en) 1994-05-30
CZ15094A3 (en) 1994-07-13
TW349867B (en) 1999-01-11
ES2117052T5 (es) 2004-12-01
PH30906A (en) 1997-12-23
EP0596032B1 (en) 1998-05-27
DE69225710D1 (de) 1998-07-02
NO940218D0 (no) 1994-01-21
US6270769B1 (en) 2001-08-07
RU2129439C1 (ru) 1999-04-27
AU2433892A (en) 1993-02-23
SK282920B6 (sk) 2003-01-09
ZA925614B (en) 1993-04-20
AU666127B2 (en) 1996-02-01
FI109335B (fi) 2002-07-15
EP0596032A1 (en) 1994-05-11

Similar Documents

Publication Publication Date Title
ES2117052T3 (es) Induccion de respuestas de linfocitos t citotoxicos.
MX9704097A (es) Induccion de respuestas de linfocitos t citotoxicos.
CY1119742T1 (el) Βιολογικα συστηματα μεταφορας πολλαπλου-συστατικου
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ES2084944T3 (es) Amidas terapeuticas.
ES2130217T3 (es) Uso de tiloxapol como dispersante y estabilizante de nanoparticulas.
ES2073205T3 (es) Agentes con efecto refrigerante fisiologico y compuestos activos apropiados para estos agentes.
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
ES2103966T3 (es) Uso de una timosina en el tratamiento de hepatitis c.
PA8481501A1 (es) 4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas
MX9300603A (es) Derivados tiaciclicos de piperidinilo.
ES2153076T3 (es) Agentes herbicidas basados en bencisoxazol y bencisotiazol sustituidos.
ES2170822T3 (es) Formulacion liquida de 1,2-bencisotiazolin-3-ona.
MX17808A (es) Nuevos derivados de artemisinina,procedimiento para su preparacion y su uso como agentes antiprosoos
ES2167544T3 (es) Dioxidos de benzotiazina como antagonistas de la endotelina.
ES2062374T3 (es) Heteroarilpiperazinas, agentes antipsicoticos.
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
FI820563L (fi) Antimykotiskt medel i form av stift med hoeg frisaettning av det aktiva aemnet
ES2075359T3 (es) Composicion de cosmetico para el cabello.
ID27765A (id) Plester gel yang mengandung steroid dan proses pembuatannya
AR027688A1 (es) Acilsulfimidas heterociclicas, procedimiento para su preparacion, agentes que las contienen y su empleo como agentes para combatir animales perjudiciales
ES2116496T3 (es) Proceso para la preparacion de 1,4-disubstituido-5(4h)-tetrazolinonas.
ES2093782T3 (es) Piridazindionas y su uso en el tratamiento de trastornos neurologicos.
ES2064119T3 (es) Nuevos derivados de aminobenzosultam como inhibidores de la lipoxigenasa.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 596032

Country of ref document: ES